Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2201 to 2250 of 8236 results

  1. Magtrace/Sentimag MT599 (MIB263)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  2. Acumen IQ sensor MT616 (MIB266)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  3. HealthVCF for detecting vertebral compression fractures on CT scans MT581 (MIB267)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  4. MMprofiler for prognostic risk classification in multiple myeloma (MT623) (MIB270)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  5. Colli-pee void urine collection device (MT628) (MIB273)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MT604) (MIB268)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. PLASMA system for electrovaporisation of the prostate (MT597) (MIB274)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. MT646 Bardy Carnation Ambulatory Monitor

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  10. MT650 24/7 EEG SubQ for people with epilepsy

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  11. MT633 FreeO2 Automatic Oxygen Titration

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  12. MT656 Paige Prostate AI system for the detection of prostate cancer

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  13. MT660 CerebAir for monitoring continuous, real-time EEG

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  14. MT658 Quit Genius for Smoking Cessation

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. Rezafungin for untreated invasive candidiasis [TSID10768]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  16. Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  17. ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  18. DV7103 for treating cystinuria in people 6 months and over [TSID10438]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  19. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis [TSID11790]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  20. Macitentant–tadalafil for treating pulmonary arterial hypertension [TSID10517]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  21. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg [TSID11894]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  22. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  23. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  24. Aflibercept for untreated diabetic macular oedema [TSID10621]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  25. Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TSID10755]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  26. Rivaroxaban for treating chronic heart failure [ID1462]

    Awaiting development Reference number: GID-TA10393 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  27. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    Awaiting development Reference number: GID-TA10431 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  28. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  29. Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]

    Awaiting development Reference number: GID-TA11824 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  30. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [TSID12239]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  32. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  33. Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  34. Artificial intelligence technologies for mammography: early value assessment

    Awaiting development Reference number: GID-HTE10062 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  35. Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  36. ID6611 Obesity, overweight - semaglutide (including review of TA875)

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  37. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]

    Awaiting development Reference number: GID-TA11526 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]

    Awaiting development Reference number: GID-TA11826 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]

    Awaiting development Reference number: GID-TA11830 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  40. Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  41. Modified release hydrocortisone capsules for treating adrenal insufficiency in people 12 years and over [TSID12254]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  42. Dasiglucagon for treating severe hypoglycaemia caused by type 1 diabetes in people under 6 years [TSID12255]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  43. Bepirovirsen for treating chronic hepatitis B [ID6608]

    In development Reference number: GID-TA11803 Expected publication date: TBC

    Technology appraisal guidance
    In development

  44. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    In development Reference number: GID-TA10748 Expected publication date: TBC

    Technology appraisal guidance
    In development

  45. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  46. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development Reference number: GID-TA11040 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  47. Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]

    Awaiting development Reference number: GID-TA11800 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  48. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]

    Awaiting development Reference number: GID-TA11469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  49. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Awaiting development Reference number: GID-TA11700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  50. Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]

    Awaiting development Reference number: GID-TA11673 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development